• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Third Harmonic Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/27/25 8:10:09 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THRD alert in real time by email
    8-K
    0001923840false00019238402025-03-272025-03-27

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 27, 2025

     

     

    THIRD HARMONIC BIO, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41498

    83-4553503

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1700 Montgomery Street, Suite 210

     

    San Francisco, California

     

    94111

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (209) 727-2457

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    THRD

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On March 27, 2025, Third Harmonic Bio, Inc. (the “Company”) issued a press release reporting the Company’s financial results for the fourth quarter and full year ended December 31, 2024. A copy of the Company’s press release is attached as Exhibit 99.1 to this report.
     

    The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    Number

    Description

    99.1

    Press Release issued by Third Harmonic Bio, Inc. dated March 27, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    THIRD HARMONIC BIO, INC.

     

     

     

     

    Date:

    March 27, 2025

    By:

    /s/ Christopher Murphy

     

     

     

    Christopher Murphy
    Chief Financial and Business Officer

     


    Get the next $THRD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THRD

    DatePrice TargetRatingAnalyst
    3/28/2025$23.00 → $5.00Buy → Hold
    Stifel
    2/12/2025$20.00 → $5.00Overweight → Equal-Weight
    Morgan Stanley
    2/11/2025Outperform → Mkt Perform
    Raymond James
    8/9/2024$12.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    6/18/2024$23.00Buy
    Stifel
    6/7/2024$18.00Outperform
    Raymond James
    More analyst ratings

    $THRD
    SEC Filings

    View All

    SEC Form 15-12G filed by Third Harmonic Bio Inc.

    15-12G - Third Harmonic Bio, Inc. (0001923840) (Filer)

    8/11/25 6:03:26 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Third Harmonic Bio Inc.

    EFFECT - Third Harmonic Bio, Inc. (0001923840) (Filer)

    8/1/25 12:15:04 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Third Harmonic Bio Inc.

    8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)

    7/31/25 2:40:34 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

    Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in the third quarter of 2025 THB335 demonstrated 85% serum tryptase reduction with an encouraging safety profile in an additional Phase 1 cohort evaluating 100mg dose with new drug product capsule formulation Company initiating a sale process of THB335 SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD) today announced that its stockholders overwhelmingly approved the previously proposed Plan of Liquidation and

    6/12/25 8:00:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Third Harmonic Bio Announces Plan of Liquidation and Dissolution

    Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 Initial distribution expected in the range between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock, expected in the third quarter of 2025 Sale of the Company's assets, including THB335, to be initiated pending stockholder approval of the Plan of Liquidation and Dissolution SAN FRANCISCO, April 14, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD) today announced that the Company's board of directors, after considering opportunities to

    4/14/25 6:45:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

    Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across all assets in the company Strong financial position with cash and cash equivalents totaling $285.1 million as of December 31, 2024 SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024. THB335 Phase 1 Clinical Results In February 2025, the Company reported resu

    3/27/25 8:10:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Holles Natalie C. disposed of 1,218,836 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

    8/14/25 4:09:05 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Seidel Hans Martin disposed of 85,753 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

    8/14/25 4:06:24 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Soloway Thomas P

    4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

    8/14/25 4:05:41 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Third Harmonic Bio downgraded by Stifel with a new price target

    Stifel downgraded Third Harmonic Bio from Buy to Hold and set a new price target of $5.00 from $23.00 previously

    3/28/25 8:16:37 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Third Harmonic Bio downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Third Harmonic Bio from Overweight to Equal-Weight and set a new price target of $5.00 from $20.00 previously

    2/12/25 7:12:21 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Third Harmonic Bio downgraded by Raymond James

    Raymond James downgraded Third Harmonic Bio from Outperform to Mkt Perform

    2/11/25 11:05:35 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Leadership Updates

    Live Leadership Updates

    View All

    Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

    SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. "Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "Beyond his expertise, Geoff is an excellent cultural fit with our organ

    3/28/24 8:30:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update

    Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion; Pre-IND interaction with the U.S. FDA now complete Program remains on track to file a U.S. IND and initiate a Phase 1 study of THB335 during the first half of 2024 SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Christopher Murphy as Chief Financial and Business Officer. Chris brings extensive experience in business de

    1/4/24 8:00:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Third Harmonic Bio Inc.

    SC 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

    11/14/24 5:46:12 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Third Harmonic Bio Inc.

    SC 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)

    11/14/24 1:28:35 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Third Harmonic Bio Inc.

    SC 13D/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

    11/12/24 6:04:36 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRD
    Financials

    Live finance-specific insights

    View All

    Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

    THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today

    2/11/25 7:00:00 AM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care